Olaf-Georg Issinger

Prof. Dr. Olaf-Georg Issinger

Department of Biochemistry and Molecular Biology, University of Southern Denmark, 5230 Odense M, Denmark
orcid

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
Barbara GuerraBarbara Guerra
Barbara Guerra
Olaf-Georg IssingerOlaf-Georg Issinger
Olaf-Georg Issinger
The need for new drugs is compelling, irrespective of the disease. Focusing on medical problems in the Western countries, heart disease and cancer are at the moment predominant illnesses. Owing to the fact that ~90% of all 21,000 cellular proteins in humans are regulated by phosphorylation/dephosphorylation it is not surprising that the enzymes catalysing these reactions (i.e., protein kinases and phosphatases, respectively) have attracted considerable attention in the recent past. Protein kinases are major team players in cell signalling. In tumours, these enzymes are found to be mutated disturbing the proper function of signalling pathways and leading to uncontrolled cellular growth and sustained malignant behaviour. Hence, the search for small-molecule inhibitors targeting the altered protein kinase molecules in tumour cells has become a major research focus in the academia and pharmaceutical companies.

1 January 2015 in Cancer Letters
Verified
Journal Article
Closed access
Barbara GuerraBarbara Guerra
Barbara Guerra
TRTine D.L. Rasmussen
Tine D.L. Rasmussen
ASAlexander Schnitzler
Alexander Schnitzler
HJHans H. Jensen
Hans H. Jensen
BBBrigitte S. Boldyreff
Brigitte S. Boldyreff
Olaf-Georg IssingerOlaf-Georg Issinger
Olaf-Georg Issinger


1 February 2019 in Colloids and Surfaces B: Biointerfaces
Verified
Journal Article
Open access
MSMai Bay Stie
Mai Bay Stie
HTHenrik Seir Thoke
Henrik Seir Thoke
Olaf-Georg IssingerOlaf-Georg Issinger
Olaf-Georg Issinger
JHJennifer Hochscherf
Jennifer Hochscherf
Barbara GuerraBarbara Guerra
Barbara Guerra
Lars Folke OlsenLars Folke Olsen
Lars Folke Olsen
We have successfully encapsulated two proteins, bovine serum albumin (BSA) and p53, in chitosan-tripolyphosphate (TPP) nanoparticles at various pH values from 5.5 to 6.5 and delivered the particles to human melanoma cells. The particles have diameters ranging from 180 nm to 280 nm and a zeta potential of +15 to + 40 mV. Cellular uptake of the particles by human skin melanoma cells was evaluated by: (i) fluorescence microscopy and (ii) gel electrophoresis showing that FITC-labeled BSA and p53 could be recovered in the soluble cell fraction after lysis of the cells. Our data also show that the highest cellular uptake takes place at the lowest pH as the particles have the highest positive charge under these conditions. The method we describe appears to be a general method for delivery of proteins to cells using chitosan-TPP nanoparticles as a drug delivery system, since structurally unrelated proteins such as BSA and p53 with different isoelectrical points can be encapsulated in the chitosan-TPP nanoparticles and be effectively internalized by the cells.

13 December 2010 in Biochemistry
Verified
Journal Article
Closed access
JRJennifer Raaf
Jennifer Raaf
NBNils Bischoff
Nils Bischoff
KKKarsten Klopffleisch
Karsten Klopffleisch
EBElena Brunstein
Elena Brunstein
BOBirgitte Brinkmann Olsen
Birgitte Brinkmann Olsen
Karsten NiefindKarsten Niefind
Karsten Niefind

29 November 2016 in Oncotarget
Verified
Journal Article
Open access
MRMaj Rabjerg
Maj Rabjerg
Barbara GuerraBarbara Guerra
Barbara Guerra
AOAida Oliván-Viguera
Aida Oliván-Viguera
MMMinne Line Nedergaard Mikkelsen
Minne Line Nedergaard Mikkelsen
RKRalf Kohler
Ralf Kohler
NMNiels Marcussen
Niels Marcussen
Nuclear localization of the CK2-subunit correlates with poor prognosis in clear cell renal cell carcinoma